BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE ...
In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...
Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.
A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.
Microbial neutralization must constantly achieve a six-log reduction threshold of Geobacillus stearothermophilus and comply ...
The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...
ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in subjects with GA ...
The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and ...
Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...
Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback